Business of Cannabis | Europe

The Czech Republic is entering a new political era following its recent elections, but what does this mean for cannabis reform? Despite uncertainty, industry voices suggest upcoming decriminalisation and medical reforms are likely to stay on track, even under a potential Babiš-led government. With key pro-reform MPs returning to parliament, the country’s progressive approach may prove resilient. Will the Czech Republic remain Europe’s quiet leader in cannabis policy? #CzechRepublic #CannabisReform #DrugPolicy

Tilray Brands, Inc., Corbus Pharmaceuticals, and STENOCARE A/S are showing renewed momentum in the cannabis and biotech sectors. Tilray posted strong Q1 2025 results, Corbus received FDA Fast Track designation for its oncology programme, and Stenocare delivered one of its strongest Nordic quarters with share price gains over 120%. These developments highlight how operational progress, regulatory milestones, and market confidence are driving renewed investor attention. Which of these companies do you think has the most potential to maintain momentum through the rest of 2025? #CannabisIndustry #Stocks #CannabisBusiness

Alternaleaf Alternaleaf UK has launched the UK’s first women’s health service dedicated to cannabis-based treatments for gynaecological and hormonal conditions. Led by Medical Director Dr Nabila Chaudhri, the new unit aims to close the gender care gap as more women seek alternatives to painkillers and face growing NHS waiting lists. With the number of female patients rising rapidly, Alternaleaf says medical cannabis could offer a safer, more targeted option for conditions such as endometriosis and perimenopause. Could this signal a turning point for women’s health and cannabis-based medicine in the UK?

Nearly 18 months after Germany’s Cannabis Act (CanG) came into force, legal cannabis supply channels are overtaking the illicit market. A new survey from Frankfurt and Freiburg universities shows that home cultivation and pharmacy purchases are now the preferred sources for most adults, while public purchases and illegal channels have dropped sharply. Consumption remains largely private, with joints and vaporisers leading the way. These findings provide important insights for policymakers ahead of the federal government’s official evaluation, highlighting a clear shift in public behaviour and perception since legalisation. How do you think Germany’s shift to legal supply channels will impact the future of cannabis policy?

Nearly 18 months after Germany introduced the Recreational Cannabis Act (KCanG), not a single pilot project has been approved. These scientifically monitored projects were meant to allow the legal sale of cannabis at authorised distribution points and form the second pillar of Germany’s partial legalisation. Now, a group of leading researchers is calling on the federal government to approve applications without further delay, warning that without pilot projects, evidence-based drug policy in Germany remains out of reach. How do you think delayed pilot projects impact Germany’s ability to implement rational cannabis policy? Hit the link in comments 👇

VERTANICAL's Phase 3 clinical trial results for its chronic pain treatment have been widely reported, but the true significance of these Randomised Controlled Trial (RCT) findings has been understated. While patients and prescribers already recognise the efficacy of cannabis for chronic pain, integrating these treatments into mainstream healthcare still depends on robust clinical data. With approval in Germany and access to the wider European market through the mutual recognition procedure, Vertanical has taken a major step toward providing that evidence. As the first multi-compound cannabis medicine to pass an RCT, VER-01 advances the case that cannabis can be a safer, more effective alternative to opioids. Could this be the breakthrough that finally brings cannabis into the pharmaceutical mainstream? Hit the link below to read more 👇

“Right now, the lack of harmonisation creates uncertainty. Once Europe builds a stable regulatory backbone, medical cannabis will no longer be viewed as a speculative play but as a healthcare asset class. That’s when the sector will see the kind of structured capital, from pension funds, healthcare investors, and impact funds, that it truly deserves.” As PHCANN INTERNATIONAL launches its new premium range of products across the UK and Germany, we sat down with its CEO, Sasho Stefanoski,PhD to discuss everything from the future of #EU-GMP to why trust, not hype, will determine the industry’s long-term credibility.

Solihull Health Check Clinic has rebranded as Airmed Clinic, in partnership with The VOR Group and My Dispensary. The relaunch introduces new pricing, expanded prescriber teams, and the MyPAS access scheme, improving affordability and transparency for UK medical cannabis patients. #MedicalCannabis #UKHealthcare #CannabisAccess https://lnkd.in/eN9ZfG-a

Germany’s Federal Cabinet has approved proposed new restrictions on medical cannabis, laying the path for the bill to be debated in the German parliament. The country's pioneering cannabis reforms are now being fully politicised, with the government citing a 'worrying' trend of cannabis misuse, despite its own recently published data suggesting otherwise. 🔗 Read our full analysis: https://lnkd.in/eCcqnqyu #CannabisPolicy #Germany #MedicalCannabis

The UK and Germany are leading Europe’s medical cannabis boom, but their paths are very different. Releaf’s CEO Tim Kirby says: “A lot of operators in Germany are drinking their own champagne. It’s very easy to feel successful when there’s huge demand, but that doesn’t mean you’re good at it.” Since launching in February 2024, Releaf has grown into one of the UK’s largest clinics, serving 300 patients a day and attracting 300,000 monthly visitors to its site. Now, the clinic is bringing its tech-focused, patient-first digital ecosystem to Germany, aiming to be a top-three clinic within six months. 🔗 https://lnkd.in/entjV9b7 Could this approach redefine the German medical cannabis market?